)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Renalytix
Renalytix (RENX) investor relations material
Renalytix H2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H2 2026 earnings summary28 Oct, 2026
Executive summary
Unaudited results for the 12 months to 30 June 2026: revenue held at $3.0M; underlying EBITDA loss narrowed to $12.1M from $14.0M.
Commercial reach expanded with 233+ physicians onboarded, 10 fully integrated practices versus two, and successful integrations across Epic, athenahealth and eClinicalWorks.
A multi-year national distribution agreement with Quest Diagnostics was signed in September 2026, with national rollout planned from Q1 2027.
Financial highlights
Revenue was $3.0M in both periods; commercial testing revenue declined to $2.2M from $2.7M, while life sciences revenue rose to $0.8M from $0.3M.
Gross profit was $1.2M in both periods; cost of sales was $1.8M in both periods.
Operating loss narrowed to $14.0M from $17.2M; net loss narrowed to $14.2M from $20.4M, including a $3.5M convertible-bond settlement loss in 2025.
Basic and diluted loss per share improved to $0.03 from $0.07.
Administrative expenses fell to $15.2M from $18.4M; underlying EBITDA loss improved to $12.1M from $14.0M, excluding share-based payments, severance, depreciation and amortisation.
Outlook and guidance
National launch with Quest Diagnostics is planned for Q1 2027; testing growth is expected to accelerate into H2 2027 and beyond.
Current forecasts indicate cash runway of ~12 months from the report date; cash burn is expected to decline as testing volumes increase and operating leverage improves.
Laboratory automation and expanded facility capacity support a target annual testing throughput of 200,000 in 2028.
Audited results for the 18-month period ending 31 December 2026 are expected by 30 June 2027 following the accounting reference date change.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Renalytix
- Quest Diagnostics partnership enables national scale-up and margin gains for KidneyIntelX.RENX
Investor update - Revenue up, losses narrowed, and funding secured as integration-led growth accelerates.RENXH1 2026
- FY26 revenue guidance raised to $4m, driven by new EMR integrations and hospital pilot.RENXH1 2026 TU
- 26.8M shares registered for resale post-private placement; strategic review and compliance risks ongoing.RENXRegistration Filing
- Registration enables resale of 26.8M shares from a private placement; no proceeds to the company.RENXRegistration Filing
- Resale registration for 26.8M shares amid Nasdaq delisting risk and strategic review.RENXRegistration Filing
- Revenue up 30% to $3.0M, gross margin 40%, net loss $20.4M; growth driven by partnerships and cost cuts.RENXQ4 2025
- AGM to vote on financials, compensation, auditor appointments, and share authorities.RENXProxy Filing
- 20% revenue growth, improved margins, and cost cuts, but going concern risk remains.RENXQ2 2025
Next Renalytix earnings date
Transition period25 Mar, 2027
Renalytix
Next Renalytix earnings date
Transition period25 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Renalytix Plc is a diagnostics company specializing in the development of tests that assess kidney health. The company integrates machine learning and clinical data to create predictive diagnostics aimed at improving kidney disease treatment. It serves healthcare providers and institutions through strategic collaborations and commercialization efforts. Renalytix Plc is headquartered in London, United Kingdom, and its shares are listed on the NASDAQ.